JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

10.4 0.87

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.2

Max

10.65

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.7M

-66M

Verkoop

1.2M

15M

Winstmarge

-432.509

Werknemers

192

EBITDA

-8M

-73M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+153.41% upside

Dividenden

By Dow Jones

Volgende Winsten

4 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

411M

958M

Vorige openingsprijs

9.53

Vorige sluitingsprijs

10.4

Nieuwssentiment

By Acuity

50%

50%

168 / 373 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 okt 2025, 23:32 UTC

Populaire aandelen

Stocks to Watch: Amazon, Reddit, SPS Commerce

30 okt 2025, 23:02 UTC

Winsten

AIA Group 3Q Value of New Business Grew

30 okt 2025, 23:45 UTC

Marktinformatie

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30 okt 2025, 23:00 UTC

Winsten

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30 okt 2025, 22:59 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

30 okt 2025, 22:59 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30 okt 2025, 22:56 UTC

Marktinformatie

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30 okt 2025, 22:35 UTC

Winsten

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30 okt 2025, 22:35 UTC

Winsten

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30 okt 2025, 22:31 UTC

Winsten

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30 okt 2025, 22:29 UTC

Winsten

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30 okt 2025, 22:27 UTC

Winsten

Minas Buenaventura 3Q EPS 66c >BVN

30 okt 2025, 22:27 UTC

Winsten

Minas Buenaventura 3Q Rev $431M >BVN

30 okt 2025, 22:27 UTC

Winsten

Minas Buenaventura 3Q Net $179M >BVN

30 okt 2025, 22:16 UTC

Marktinformatie
Winsten

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30 okt 2025, 22:14 UTC

Winsten

Review & Preview: A Tech Earnings Storm -- Barrons.com

30 okt 2025, 22:00 UTC

Winsten
Acquisities, Fusies, Overnames

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30 okt 2025, 21:39 UTC

Winsten

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 okt 2025, 21:26 UTC

Winsten

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 okt 2025, 21:14 UTC

Marktinformatie
Winsten

Apple Sees Record Quarterly Services Revenue -- Market Talk

30 okt 2025, 21:09 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

30 okt 2025, 21:09 UTC

Marktinformatie
Winsten

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30 okt 2025, 21:04 UTC

Winsten

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30 okt 2025, 21:03 UTC

Winsten

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30 okt 2025, 21:03 UTC

Winsten

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold Skouries on Track for 1Q of 2026

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold 3Q Adj EPS 41c >EGO

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold 3Q Rev $434.7M >EGO

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold 3Q Net $56M >EGO

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold 3Q EPS 27c >EGO

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

153.41% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 26 USD  153.41%

Hoogste 40 USD

Laagste 11 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technische score

By Trading Central

5.575 / 6.6Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

168 / 373 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat